A study on awareness of Breast Carcinoma amongst the women aged 15 years and above in Urban slums of Turbhe, Navi Mumbai

Background: Breast cancer is second most important cancer among Indian women. In India, the number of new breast cancer cases is about 115,000 per year. Although risk factors are not much prevalent as in western countries, incidence rate is increasing in India. Breast cancer awareness is an effort to raise awareness and reduce the stigma of breast cancer through education on symptoms and treatment. Objectives: Present study has the objective to assess the level of awareness about Carcinoma Breast and to study the knowledge and practice regarding screening methods of breast carcinoma Material & Methods: A cross sectional study was conducted among 160 women aged 15 years & above by simple random sampling. Pretested preformed questionnaire was used. Verbal consent was taken prior to interview. Data analysis was done by SPSS version 20 & MS Office Excel 2007. Results: 58.7% women had no knowledge regarding breast carcinoma. 93.12% women had no knowledge regarding risk factors of it. Only 8 women had knowledge about Breast Self Examination and amongst them only 2 practice it. Only 2 women had knowledge about mammography and MRI as screening method. Conclusion: Majority of women had no knowledge regarding Risk factors & Screening methods of Breast Ca. Education has positive impact on knowledge of symptoms of breast carcinoma

Product Purchase Recommendation Of User By Data Analysis Using Data Mining

With the boom of social media, it is a very popular trend for people to share what they are doing with friends across various social networking platforms. Nowadays, we have a vast amount of descriptions, comments, and ratings for local services. The information is valuable for new users to judge whether the services meet their requirements before partaking. In this paper, we propose a user-service rating prediction approach by exploring social users’ rating behaviors. In order to predict user-service ratings, we focus on users’ rating behaviors. In our opinion, the rating behavior in recommender system could be embodied in these aspects: 1) when user rated the item, what the rating is, 2) what the item is, 3) what the user interest that we could dig from his/her rating records is, and 4) how the user’s rating behavior diffuses among his/her social friends. Therefore, we propose a concept of the rating schedule to represent users’ daily rating behaviors. In addition, we propose the factor of interpersonal rating behavior diffusion to deep understand users’ rating behaviors. In the proposed user-service rating prediction approach, we fuse four factors, user personal interest (related to user and the item’s topics), interpersonal interest similarity (related to user interest), interpersonal rating behavior similarity (related to users’ rating behavior habits), and interpersonal rating behavior diffusion (related to users’ behavior diffusions), into a unified matrix-factorized framework. We conduct a series of experiments in Yelp dataset and Douban Movie dataset. Experimental results show the effectiveness of our approach

Analysis of Complement Receptor Type 1 (CR1) Polymorphisms and Its Association With Malaria in Rural Population of Maharashtra

The interaction between human host and the Plasmodium parasite is complex. The factors affecting the causality of infection and its severity are yet not completely understood. Single Nucleotide Polymorphisms (SNP) associated with CR1 may be associated with patho-physiology of malaria and its susceptibility to the disease. Methods: The objective of the present study was to calculate the incidence of various antigens of Knops blood group system and CR1 Exon22 polymorphisms in rural population from Chiplun Taluka of Ratnagiri district. The study included 112 malaria positive cases and 909 healthy controls, which were screened for CR1 Exon22 polymorphism. Knops (Kna/b), McCoy (McCa/b), Swain-Langley (Sl1/2) polymorphisms were screened in 93 cases and 321 healthy controls. The frequencies were determined using a PCR-RFLP technique. Results: Only wild types of the allele form were observed in Knops blood group system in malaria cases and healthy control. CR1 exon22 polymorphism was seen in the study population with all the 3 allele type distributed in the cases and control samples. No significant allelic or genotypic differences were found between the controls and the disease groups. Conclusion: The results of the present study demonstrate that common CR1 Exon22 and Knops blood group system are not associated with malaria in the endemic area

PLAS-20k: Extended Dataset of Protein-Ligand Affinities from MD Simulations for Machine Learning Applications

Computing binding affinities is of great importance in drug discovery pipeline and its prediction using advanced machine learning methods still remains a major challenge as the existing datasets and models do not consider the dynamic features of protein-ligand interactions. To this end, we have developed PLAS-20k dataset, an extension of previously developed PLAS-5k, with 97,500 independent simulations on a total of 19,500 different protein-ligand complexes. Our results show good correlation with the available experimental values, performing better than docking scores. This holds true even for a subset of ligands that follows Lipinski’s rule, and for diverse clusters of complex structures, thereby highlighting the importance of PLAS-20k dataset in developing new ML models. Along with this, our dataset is also beneficial in classifying strong and weak binders compared to docking. Further, OnionNet model has been retrained on PLAS-20k dataset and is provided as a baseline for the prediction of binding affinities. We believe that large-scale MD-based datasets along with trajectories will form new synergy, paving the way for accelerating drug discovery

PLAS-20k: Extended Dataset of Protein-Ligand Affinities from MD Simulations for Machine Learning Applications

Abstract Computing binding affinities is of great importance in drug discovery pipeline and its prediction using advanced machine learning methods still remains a major challenge as the existing datasets and models do not consider the dynamic features of protein-ligand interactions. To this end, we have developed PLAS-20k dataset, an extension of previously developed PLAS-5k, with 97,500 independent simulations on a total of 19,500 different protein-ligand complexes. Our results show good correlation with the available experimental values, performing better than docking scores. This holds true even for a subset of ligands that follows Lipinski’s rule, and for diverse clusters of complex structures, thereby highlighting the importance of PLAS-20k dataset in developing new ML models. Along with this, our dataset is also beneficial in classifying strong and weak binders compared to docking. Further, OnionNet model has been retrained on PLAS-20k dataset and is provided as a baseline for the prediction of binding affinities. We believe that large-scale MD-based datasets along with trajectories will form new synergy, paving the way for accelerating drug discovery

Abstracts of AICTE Sponsored International Conference on Post-COVID Symptoms and Complications in Health

This book presents the selected abstracts of the International Conference on Post-COVID Symptoms and Complications in Health, hosted from the 28th to 29th of April 2022 in virtual mode by the LR Institute of Pharmacy, Solan (H.P.)-173223 in Collaboration with AICTE, New Delhi. This conference focuses on the implications of long-term symptoms on public health, ways to mitigate these complications, improve understanding of the disease process in COVID-19 patients, use of computational methods and artificial intelligence in predicting complications, and the role of various drug delivery systems in combating the complications. Conference Title:  International Conference on Post-COVID Symptoms and Complications in HealthConference Sponsor: AICTE, New Delhi.Conference Date: 28-29 April 2022Conference Location: OnlineConference Organizer: LR Institute of Pharmacy, Solan (H.P.)-173223

Abstracts of AICTE Sponsored International Conference on Post-COVID Symptoms and Complications in Health

This book presents the selected abstracts of the International Conference on Post-COVID Symptoms and Complications in Health, hosted from the 28th to 29th of April 2022 in virtual mode by the LR Institute of Pharmacy, Solan (H.P.)-173223 in Collaboration with AICTE, New Delhi. This conference focuses on the implications of long-term symptoms on public health, ways to mitigate these complications, improve understanding of the disease process in COVID-19 patients, use of computational methods and artificial intelligence in predicting complications, and the role of various drug delivery systems in combating the complications. Conference Title:  International Conference on Post-COVID Symptoms and Complications in HealthConference Sponsor: AICTE, New Delhi.Conference Date: 28-29 April 2022Conference Location: OnlineConference Organizer: LR Institute of Pharmacy, Solan (H.P.)-173223

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee